Esteroides anabólicos androgênicos modificam persistentemente o perfil lipídico do usuário: relato de caso

Resumo

O objetivo do estudo foi mostrar uma modificação duradoura do perfil lipídico e dos índices aterogênicos pelo uso abusivo de esteróides anabólicos androgênicos (EAA) por um fisiculturista amador. Este estudo relata um caso de fisiculturista não-competitivo de 27 anos com graves anormalidades no perfil lipídico e nos índices aterogênicos. Ele usava esteróides anabólicos androgênicos e não tinha nenhum outro fator de risco para doença cardíaca ou fatores de risco associados. Após algumas palestras educacionais, ele decidiu continuar seu treinamento sem o uso de esteróides anabólicos androgênicos ou quaisquer drogas ergogênicas ilegais. O perfil lipídico e os índices aterogênicos voltaram aos valores normais no terceiro teste laboratorial feito cinco anos após seu último ciclo de EAA. O abuso de esteróides anabólicos androgênicos pode promover aumento do risco de doenças cardiovasculares, uma característica que pode persistir por muitos anos depois mesmo após a interrupção do uso de esteróides anabólicos androgênicos.

Palavras-chave: Esteróides anabólicos androgênicos, Fisiculturista, Doenças cardíacas, Anormalidades cardiovasculares, Arteriosclerose, HDL

Referências

Ahlgrim, C., & Guglin, M. (2009). Anabolics and cardiomyopathy in a bodybuilder: case report and literature review. Journal of cardiac failure, 15(6), 496-500. https://doi.org/10.1016/j.cardfail.2008.12.014

Ajayi, A.A., Mathur, R., & Halushka, P.V. (1995). Testosterone increases human platelet thromboxane A2 receptor density and aggregation responses. Circulation, 91(11), 2742-2747. https://doi.org/10.1161/01.CIR.91.11.2742

Angell, P., Chester, N., Green, D., Somauroo, J., Whyte, G., & George, K. (2012). Anabolic steroids and cardiovascular risk. Sports medicine, 42(2), 119-134. https://goo.gl/LR4H8V

Baggish, AL, Weiner, RB, Kanayama, G., Hudson, JI, Picard, MH, Hutter Jr, AM, & Pope Jr, HG (2010). Long-term anabolic-androgenic steroid use is associated with left ventricular dysfunction. Circulation: Heart Failure, 3(4), 472-476. https://doi.org/10.1161/CIRCHEARTFAILURE.109.931063

Basaria, S., Wahlstrom, J.T., & Dobs, A.S. (2001). Anabolic-androgenic steroid therapy in the treatment of chronic diseases. The Journal of Clinical Endocrinology & Metabolism, 86(11), 5108-5117. https://doi.org/10.1210/jcem.86.11.7983

Blue, J.G., & Lombardo, J.A. (1999). Steroids and steroid-like compounds. Clinics in Sports Medicine, 18(3), 667-689. https://doi.org/10.1016/S0278-5919(05)70175-7

Castelli, W.P., Garrison, R.J., Wilson, P.W., Abbott, R.D., Kalousdian, S., & Kannel, W.B. (1986). Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. Jama, 256(20), 2835-2838. https://doi.org/10.1001jama.1986.03380200073024

Dobiasova, M., Urbanova, Z., & Samanek, M. (2005). Relations between particle size of HDL and LDL lipoproteins and cholesterol esterification rate. Physiol Res, 54(159), e65. http://www.biomed.cas.cz/physiolres/pdf/54/54_159.pdf

Far, H.R.M., Ågren, G., & Thiblin, I. (2012). Cardiac hypertrophy in deceased users of anabolic androgenic steroids: an investigation of autopsy findings. Cardiovascular Pathology, 21(4), 312-316. https://doi.org/10.1016/j.carpath.2011.10.002

Fernandez, M.L., & Webb, D. (2008). The LDL to HDL cholesterol ratio as a valuable tool to evaluate coronary heart disease risk. Journal of the American College of Nutrition, 27(1), 1-5. https://doi.org/10.1080/07315724.2008.10719668

Gårevik, N., Strahm, E., Garle, M., Lundmark, J., Ståhle, L., Ekström, L., & Rane, A. (2011). Long term perturbation of endocrine parameters and cholesterol metabolism after discontinued abuse of anabolic androgenic steroids. The Journal of steroid biochemistry and molecular biology, 127(3-5), 295-300. https://doi.org/10.1016/j.jsbmb.2011.08.005

Gårevik, N., Rane, A., Björkhem-Bergman, L., Ekström, L. (2014). Effects of different doses of testosterone on gonadotropins, 25-hydroxyvitamin D3, and blood lipids in healthy men. Substance Abuse and Rehabilitation, 5, 121-127. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266340/.

Glazer, G. (1991). Atherogenic effects of anabolic steroids on serum lipid levels: a literature review. Archives of internal medicine, 151(10), 1925-1933. https://doi.org/10.1001/archinte.1991.00400100013003

Hengevoss, J., Piechotta, M., Müller, D., Hanft, F., Parr, MK Schänzer, W., Diel, P. (2015). Combined effects of androgen anabolic steroids and physical activity on the hypothalamic-pituitary-gonadal axis. Journal of Steroid Biochemistry and Molecular Biology, 150, 86–96. http://dx.doi.org/10.1016/j.jsbmb.2015.03.003.

Henning, A. (2017). Challenges to promoting health for amateur athletes through anti-doping policy. Drugs: Education, prevention and policy, 24(3), 306-313. https://doi.org/10.1080/09687637.2016.1208732

Hislop, M.S., Ratanjee, B.D., Soule, S.G., & Marais, A.D. (1999). Effects of anabolic-androgenic steroid use or gonadal testosterone suppression on serum leptin concentration in men. European journal of endocrinology, 141(1), 40-46. https://doi.org/10.1530/eje.0.1410040.

Ip, E.J., Barnett, M.J., Tenerowicz, M.J., & Perry, P.J. (2011). The Anabolic 500 survey: Characteristics of male users versus nonusers of anabolic‐androgenic steroids for strength training. Pharmacotherapy: The journal of human pharmacology and drug therapy, 31(8), 757-766. https://doi.org/10.1592/phco.31.8.757

Irwig, MS, Fleseriu, M., Jonklaas, J., Tritos, NA, Yuen, KCJ, Correa, R., Elhomsy, G., Gaarla, V., Jsaim, S., Soe, K., Baldeweg, SE, Boguszewski, CL, & Bancos, I. (2020). Off-Label Use and Misuse of Testosterone, Growth Hormone, Thyroid Hormone, and Adrenal Supplements: Risks and Costs of a Growing Problem. Endocrine Practice, 26(3), 340–353. https://doi.org/10.4158/ps-2019-0540

Kanayama, G., & Pope Jr, H.G. (2018). History and epidemiology of anabolic androgens in athletes and non-athletes. Molecular and Cellular Endocrinology, 464, 4-13. https://doi.org/10.1016/j.mce.2017.02.039

Karila, T., Laaksonen, R., Jokelainen, K., Himberg, J.J., & Seppälä, T. (1996). The effects of anabolic androgenic steroids on serum ubiquinone and dolichol levels among steroid abusers. Metabolism, 45(7), 844-847. https://doi.org/10.1016/S0026-0495(96)90157-2

Leit, R.A., Pope Jr, H.G., & Gray, J.J. (2001). Cultural expectations of muscularity in men: The evolution of Playgirl centerfolds. International Journal of eating disorders, 29(1), 90-93. https://psycnet.apa.org/record/2001-16082-015

Maravelias, C., Dona, A., Stefanidou, M., & Spiliopoulou, C. (2005). Adverse effects of anabolic steroids in athletes: a constant threat. Toxicology letters, 158(3), 167-175. https://doi.org/10.1016/j.toxlet.2005.06.005

Mann, S., Beedie, C., & Jimenez, A. (2014). Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations. Sports Medicine, 44(2), 211–221. https://doi.org/10.1007/s40279-013-0110-5

Marqueti, R.C., Micocci, K.C., Leite, R.D., & Selistre-de-Araujo, H.S. (2012). Nandrolone inhibits MMP-2 in the left ventricle of rats. International journal of sports medicine, 33(03), 181-185. https://doi.org/10.1055/s-0031-1291252

Millán, J., Pintó, X., Muñoz, A., Zúñiga, M., Rubiés-Prat, J., Pallardo, LF, Masana, L, Mangas, A, Hernández-Mijares, A, González-Santos, P, Ascaso, JF, & Pedro-Botet, J. (2009). Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vascular health and risk management, 5, 757. https://doi.org/10.2147/VHRM.S6269

Montisci, M., El Mazloum, R., Cecchetto, G., Terranova, C., Ferrara, SD, Thiene, G., & Basso, C. (2012). Anabolic androgenic steroids abuse and cardiac death in athletes: morphological and toxicological findings in four fatal cases. Forensic science international, 217(1-3), e13-e18. https://doi.org/10.1016/j.forsciint.2011.10.032

Nieminen, MS, Rämö, MP, Viitasalo, M., Heikkilä, P., Karjalainen, J., Mäntysaari, M., & Heikkila, J. (1996). Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters. European heart journal, 17(10), 1576-1583. https://doi.org/10.1093/oxfordjournals.eurheartj.a014724

Nwagha, U.I., Ikekpeazu, E.J., Ejezie, F.E., Neboh, E.E., & Maduka, I. (2010). Atherogenic index of plasma as useful predictor of cardiovascular risk among postmenopausal women in Enugu, Nigeria. African health sciences, 10(3). https://goo.gl/UoXHkP

Palacios, A., Campfield, L.A., McClure, R.D., Steiner, B., & Swerdloff, R.S. (1983). Effect of testosterone enanthate on hematopoiesis in normal men. Fertility and Sterility, 40(1), 100-104. https://doi.org/10.1016/S0015-0282(16)47185-2

Parkinson, A.B., & Evans, N.A. (2006). Anabolic androgenic steroids: a survey of 500 users. Medicine and science in sports and exercise, 38(4), 644-651. https://doi.org/10.1249/01.mss.0000210194.56834.5d

Pertusi, R., Dickerman, R.D., & McConathy, W.J. (2001). Evaluation of aminotransferase elevations in a bodybuilder using anabolic steroids: hepatitis or rhabdomyolysis? The Journal of the American Osteopathic Association, 101(7), 391-394. https://goo.gl/Vfrfta

Pettersson, J., Hindorf, U., Persson, P., Bengtsson, T., Malmqvist, U., Werkström, V., & Ekelund, M. (2008). Muscular exercise can cause highly pathological liver function tests in healthy men. British journal of clinical pharmacology, 65(2), 253-259. https://doi.org/10.1111/j.1365-2125.2007.03001.x

Pope, H.G., Kouri, E.M., & Hudson, J.I. (2000). Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Archives of general psychiatry, 57(2), 133-140. https://doi.org/10.1001/archpsyc.57.2.133

Pope Jr, H.G., Olivardia, R., Gruber, A., & Borowiecki, J. (1999). Evolving ideals of male body image as seen through action toys. International journal of eating disorders, 26(1), 65-72. https://doi.org/10.1002/(sici)1098-108x(199907)26:1%3C65::aid-eat8%3E3.0.co;2-d

Sagoe, D., Molde, H., Andreassen, C.S., Torsheim, T., & Pallesen, S. (2014). The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Annals of epidemiology, 24(5), 383-398. https://doi.org/10.1016/j.annepidem.2014.01.009

Santamarina, R.D., Besocke, A.G., Romano, L.M., Ioli, P.L., & Gonorazky, S.E. (2008). Ischemic stroke related to anabolic abuse. Clinical neuropharmacology, 31(2), 80-85. https://doi.org/10.1097/WNF.0b013e3180ed4485

Santora, LJ, Marin, J., Vangrow, J., Minegar, C., Robinson, M., Mora, J., & Frieds, G. (2006). Coronary calcification in body builders using anabolic steroids. Preventive cardiology, 9(4), 198-201. https://doi.org/10.1111/j.1559-4564.2006.05210.x

Schmidt, W., Biermann, B., Winchenbach, P., Lison, S., & Boning, D. (2000). How valid is the determination of hematocrit values to detect blood manipulations?. International journal of sports medicine, 21(2), 133-138. https://doi.org/10.1055/s-2000-8871.

Schwingel, PA, Cotrim, HP, Salles, BR, Almeida, CE, dos Santos Jr, CR, Nachef, B., Andrade, AR, & Zoppi, CC (2011). Anabolic‐androgenic steroids: A possible new risk factor of toxicant‐associated fatty liver disease. Liver International, 31(3), 348-353. https://doi.org/10.1111/j.1478-3231.2010.02346.x

Shahidi, N.T. (1973). Androgens and erythropoiesis. New England Journal of Medicine, 289(2), 72-80. https://doi.org/10.1056/NEJM197307122890205

Urhausen, A., Albers, T., & Kindermann, W. (2004). Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Heart, 90(5), 496-501. http://dx.doi.org/10.1136/hrt.2003.015719

Veras, K., Silva-Junior, F., L., Lima-Silva, A., E., De-Oliveira, F., R., & Pires, F.O. (2015) Impaired Physical Performance and Clinical Responses after a recreational bodybuilder’s self-administration of steroids: A Case Report. The World Journal of Men’s Health, 33(3), 209-213. http://dx.doi.org/10.5534/wjmh.2015.33.3.209

World Health Organization (1995). Physical status: The use of and interpretation of anthropometry, Report of a WHO Expert Committee. World Health Organization. https://doi.org/10.1002/(SICI)1520-6300(1996)8:6<786::AID-AJHB11>3.0.CO;2-I

Biografias Autor

Gustavo Casimiro-Lopes,

http://lattes.cnpq.br/8143521576246390

Gabriel Boaventura da Cunha,

http://lattes.cnpq.br/7611953102115785

Publicado
2022-07-08
Como Citar
Casimiro-Lopes, G., & Cunha, G. B. da. (2022). Esteroides anabólicos androgênicos modificam persistentemente o perfil lipídico do usuário: relato de caso. Lecturas: Educación Física Y Deportes, 27(290), 134-145. https://doi.org/10.46642/efd.v27i290.2672
Seção
Estudo de Caso (Clínicos)